I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | 0.00% | -2.49% | -7.11% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.11% | 142M | |
+29.68% | 681B | |
+25.07% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.68% | 235B | |
+4.71% | 199B | |
-12.43% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab